Evidence map›Paper›PMID 18765694›Full record

ArticleAntimicrobial agents and chemotherapy2008

In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical, and ultrastructural effects.

Juliany Cola Fernandes Rodrigues, Juan Luis Concepcion, Carlos Rodrigues, Aura Caldera, Julio A Urbina, Wanderley de Souza

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 82 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Frontiers in cellular and infection microbiology · 2022
    Article
  6. Unravelling the myth surrounding sterol biosynthesis as plausible target for drug design against leishmaniasis.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021
    Review
  7. Article
  8. Review
  9. Nitro-Heterocyclic compounds induce apoptosis-like effects inThe journal of venomous animals and toxins including tropical diseases · 2019
    Article
  10. Article
  11. Benzimidazole derivatives endowed with potent antileishmanial activity.Journal of enzyme inhibition and medicinal chemistry · 2018
    Article
  12. Emerging therapeutic targets for treatment of leishmaniasis.Expert opinion on therapeutic targets · 2018
    Review
  13. Induction of Early Autophagic Process onFrontiers in microbiology · 2017
    Article
  14. Article
  15. SQ109, a new drug lead for Chagas disease.Antimicrobial agents and chemotherapy · 2015
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Juliany Cola Fernandes RodriguesLaboratório de Ultraestrutura Celular Hertha Meyer, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, CCS, Ilha do Fundão, Rio de Janeiro, Brazil.
Juan Luis Concepcion
Carlos Rodrigues
Aura Caldera
Julio A Urbina
Wanderley de Souza
Instituto Venezolano de Investigaciones Científicas · VEUniversidade Federal do Rio de Janeiro · BRUniversity of the Andes · VE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ER-119884 and E5700, novel arylquinuclidine derivatives developed as cholesterol-lowering agents, were potent in vitro growth inhibitors of both proliferative stages of Leishmania amazonensis, the main causative agent of cutaneous leishmaniasis in South America, with the 50% inhibitory concentrations (IC(50)s) being in the low-nanomolar to subnanomolar range. The compounds were very potent noncompetitive inhibitors of native L. amazonensis squalene synthase (SQS), with inhibition constants also being in the nanomolar to subnanomolar range. Growth inhibition was strictly associated with the depletion of the parasite's main endogenous sterols and the concomitant accumulation of exogenous cholesterol. Using electron microscopy, we identified the intracellular structures affected by the compounds. A large number of lipid inclusions displaying different shapes and electron densities were observed after treatment with both SQS inhibitors, and these inclusions were associated with an intense disorganization of the membrane that surrounds the cell body and flagellum, as well as the endoplasmic reticulum and the Golgi complex. Cells treated with ER-119884 but not those treated with E5700 had an altered cytoskeleton organization due to an abnormal distribution of tubulin, and many were arrested at cytokinesis. A prominent contractile vacuole and a phenotype typical of programmed cell death were frequently found in drug-treated cells. The selectivity of the drugs was demonstrated with the JC-1 mitochondrial fluorescent label and by trypan blue exclusion tests with macrophages, which showed that the IC(50)s against the host cells were 4 to 5 orders of magnitude greater that those against the intracellular parasites. Taken together, our results show that ER-119884 and E5700 are unusually potent and selective inhibitors of the growth of Leishmania amazonensis, probably because of their inhibitory effects on de novo sterol biosynthesis at the level of SQS, but some of our observations indicate that ER-119884 may also interfere with other cellular processes.

Indexed as

AnimalsAntiprotozoal AgentsCytoskeletonEnzyme InhibitorsFarnesyl-Diphosphate FarnesyltransferaseHumansIn Vitro TechniquesLeishmania mexicanaLeishmaniasis, CutaneousMiceMice, Inbred BALB CProtozoan ProteinsPyridinesQuinuclidinesSterolsTubulin3-((2-benzyl-6-(3-hydroxy-4-methoxypyrrolidin-1-yl)pyridin-3-yl)ethynyl)quinuclidin-3-ol3-((2-benzyl-6-(3-methoxypropyloxy)pyridin-3-yl)ethynyl)quinuclidin-3-olAntiprotozoal AgentsEnzyme InhibitorsFarnesyl-Diphosphate FarnesyltransferaseProtozoan ProteinsPyridinesQuinuclidinesSterolsTubulin

Identifiers

PMID18765694
PMCPMC2573141
OpenAlexW2149465754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.